News

Tax in the news – impacts on biotech and tech companies

Share schemes for employees are good practice

Share schemes tax summary

By CT Team | July 13, 2017

THESE SHARE SCHEMES TABLES summarise the respective tax treatments of the three most common ways of providing equity reward to UK tax resident employees.

F-star-hi-Res-Logo

Tax structuring advice for F-star collaboration

By CT Team | June 16, 2017

CONFLUENCE Tax is delighted to have provided tax structuring advice to F-star Delta, the fourth asset-centric vehicle in the F-star family, in its recent immuno-oncology collaboration. This deal underscores the attractiveness of F-star’s asset-centric business model, which provides a flexible deal-making framework while at the same time maximises the value of F-star’s bispecific programmes and…

tennis-ball-bouncing-Wimbledon

Destination Wimbledon for Confluence Tax team

By CT Team | June 16, 2017

STRAWBERRIES, Pimm’s and, of course, tennis beckon for the Confluence Tax team this July, who will be attending Britain’s favourite tennis tournament courtesy of team boss Colin Hailey. Confluence Tax has sponsored Tennis4Cambridgeshire, a local initiative to support coaching projects, better facilities and to encourage participation by all in tennis sessions. Recent projects include free…

woman-virtual-reality-HMRC-robot

Consulting on HMRC digital improvements project

By CT Team | May 16, 2017

Confluence Tax has been invited to take part in the HMRC research project into digital improvements to its SEIS, EIS and venture capital trust schemes – a great opportunity for us to have our say on the things that bug both us and our biotech and tech clients about the tax system! This stage of the project…

Life Sciences Structured M&A: seminar Confluence Tax, Dechert, SRS

By CT Team | May 2, 2017

ON MAY 3 Confluence Tax will be jointly running a seminar on biotech M&A transactions, taking place in London. Structured deals are a key feature of Life Sciences M&A transactions based on the principle of shared risk. These involve significant contingent consideration payable to selling shareholders based on clinical, regulatory and/or sales based milestones. How you negotiate…

BioTrinity 2017 Confluence Tax

By CT Team | April 26, 2017

Confluence Tax will be attending BioTrinity 2017, Europe’s leading biopartnering and investment conference, May 8-10, Novotel London West. We’re looking forward to catching up with our clients and chatting to new delegates. Why not come by stand #35 we’re always happy to talk through the latest tax developments in relation to company structures, R&D tax credits, share schemes…

Post-budget briefing event – Thursday 9th March

By CT Team | February 15, 2017

Thursday 9th March 2017 9:00am coffee and pastries 9:30am – 10:30 briefing   Confluence Tax is pleased to invite you to a post-budget briefing to analyse how the Chancellor’s spring statement affects you and your business.   We will be offering a tailored summary of how the budget impacts the technology and biotechnology sectors and…

Colin-Hailey-of-Confluence-Tax-presenting-at-Patent-Box-Seminar

Confluence Tax patent box seminar 2016

By colinhailey | October 18, 2016

Our client seminar on the patent box, held on October 13, attracted participants from across the biotech and tech spectrum, prompting many questions and discussion points. If you missed it and would like to get to grips with the basics of the new patent box rules, have a look at the presentations. David Harris, HMRC’s…

tax-journal-asset-centric-models

Asset centric biotechnology models Tax Journal article

By colinhailey | June 20, 2016

Read and download Colin’s latest article for the Tax Journal focusing on tax issues for asset-centric biotechnology companies.  

Confluence Tax works with Capella Biosciences on their recent Series A fundraising

By colinhailey | March 14, 2016

Confluence Tax is delighted to have been able to work with Capella Biosciences on their recent Series A fundraising and Kevin Johnson of Medicxi Ventures, had this to say… “It was a pleasure to work with Confluence Tax on the Capella Series A investment.  I would not hesitate to recommend them to anyone wishing to understand…